Quality of life in patients with bone metastases from breast cancer treated with zoledronic acid
Keywords:
Health related quality of life; zoledronic acid; bone metastases; breast cancer., health related quality of life, zoledronic acid, bone metastases, breast cancerAbstract
Introduction: Bone metastases from cancer affect the health related quality of life (HRQL), but it benefits with zoledronic acid.
Methods: Were evaluated 307 patients diagnosed with bone metastases from breast cancer (2011-2013), age 18-80 years, ECOG ?3, expectancy >6 months, normal function of bone marrow/ organs, patients' follow-up for 12 months. Zoledronic acid administered each 21/28 days was the treatment used in this patients, and EORTC QLQ - BM22 module assessed HRQL.
Results: Were observed more patients aged ?50 years (69 %), postmenopausal in 62.21 %, the ductal carcinoma hormonsensitive 79.15 %.Although mixed osseous lesionspresented in 65.4 %,
<3 osseous sites in 86.9 %, and metastases in vertebras 57 %, skeletal related events were infrequent. At 12 months, zoledronic acid achieved better HRQL as were observed significant reduction in pain relating scales and psychosocial aspects, but non-in the functional interference.
Conclusions: Zoledronic acid treatment benefits HRQL in patients with bone metastases from breast cancer.
Downloads
References
Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. IntJCancer. 2013;132:1133.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30. PubMed:PMID:26742998.
Cuba. Ministerio de Salud Pública. Anuario Estadístico de Salud 2016. Dirección Nacional de Estadísticas y registros MédicosLa Habana: Ministerio de Salud Pública; 2017.
Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271-89. PubMed.PMID:27253694.
Burg MA, Adorno G, Lopez ED, Loerzel V, Stein K, Wallace C, et al. Current unmet needs of cancer survivors: analysis of open-ended responses to the American Cancer Society Study of cancer survivors II. Cancer. 2015;121:623-30. PubMed.PMID:25581252.
Ibrahim T. A new emergency in oncology: bone metastases in breast cancer patients. OncolLett. 2013;6:306-10.
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:S6243-9.
Woolf DK, Padhani AR, Makris A. Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?. Ann Oncol.2015;26:1048-57. PubMed:PMID:25471332.
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, et al. CAPG and GIPC1: breast cancer biomarkers for bone metastasis development and treatment. J Natl Cancer Inst. 2016;108:djv360. PubMed:PMID:26757732.
Cronin Fenton D, Kjærsgaard A, Nørgaard M, Amelio J.Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark. Breast Cancer Res Treat. 2018;167:517-28. PubMed.PMID:28948396.
Liede A, Jerzak KJ, Hernandez RK, Wade SW. The incidence of bone metastasis after early-stage breast cancer in Canada. Breast Cancer Res Treat.2016;156:587-95. PubMed:PMID:27083181.
Brook N, Brook E, Dharmarajan A, Dass CR, Chan A. Breast cancer bone metastases: pathogenesis and therapeutic targets. Int J BiochemCell Biol. 2018;96:63-78. PubMed.PMID:29309917.
Chen WZ, Shen JF, Zhou Y, Chen XY. Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer. Sci Rep. 2017;7:11325. PubMed:PMID:28900285.
Du WX, Duan SF, Chen JJ, Huang JF. Serum bone specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: a systematic review and meta analysis. J Cancer Res Ther. 2014;10:140-3. PubMed.PMID:25450272.
Fanale D, Amodeo V, Bazan V, Insalaco L, Incorvaia L, Barraco N, et al. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?Oncotarget. 2016;7:29321-32. PubMed.PMID:27081088.
Lebret T, Casas A, Cavo M. The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey. Eur J Cancer Care. 2017;26:e12490. PubMed.PMID:27072626.
O'Carrigan B, Wong MHF, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474. PubMed:PMID:29082518.
Oberguggenberger A, Meraner V, Sztankay M, Hilbert A, Hubalek M, Holzner B, et al.Health behavior and quality of life outcome in breast cancer survivors: prevalence rates and predictors. Clin Breast Cancer. 2018;18:38-44. PubMed:PMID:29017754.
Diel IJ. Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer. 2007;15:1243.
Ramadas A, Qureshi AM, Dominic NA, Botross NP, Riad A, ThirunavukArasoo VJ, et al. Socio-demography and medical history as predictors of health-related quality of life of breast cancer survivors. Asian Pac J Cancer Prev. 2015;16:1479-85. PubMed:PMID:25743818.
Van Roij J, Fransen H, van de Poll Franse L, Zijlstra M, Raijmakers N. Measuring health-related quality of life in patients with advanced cancer: a systematic review of self - administered measurement instruments. Qual Life Res. 2018;10:1-19.PubMed:PMID:29427216.
Soriano JL, Batista N, Lima M. Cáncer de mama localmenteavanzado, recurrente y metastásico. En: Manual de PrácticasMédicas IV Edición. UnidadFuncional de Tumores. Tomo 1. La Habana: Editorial CienciasMédicas; 2012.p.90-126.
Chow E, Nguyen J, Zhang L, Tseng LM, Hou MF, Fairchild A, et al.International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer 2012;118:1457-65.
SavciHeijink CD, Halfwerk H, Hooijer GKJ, Horlings HM, Wesseling J, van de Vijver MJ. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015;150:547-57. PubMed:PMID:25820592.
Schröder J, Fietz Th, Köhler A, Petersen V, Tesch H, Spring L,et al.Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study. Eur J Cancer. 2017;79:139-48. PubMed:PMID:28494404.
Soriano J, Batista N, Lima M, González J, Gutiérrez A, Luaces P. Evaluación del uso de ácido zoledrónico en pacientes con cáncer de mama metastásico a hueso. Rev Cubana Med. 2010;49:33-64.
Yeh DC, Chen DR, Chao TY, Chen SC, Wang HC, Rau KM, et al. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid. In Vivo. 2014;28:1001-4. PubMed:PMID:25189922.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
